Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy

被引：0
|
作者：
Takako Inoue
Madoka Kimura
Junji Uchida
Kazumi Nishino
Toru Kumagai
Junko Taniguchi
Fumio Imamura
机构：
[1] Osaka Medical Center for Cancer and Cardiovascular Disease,Department of Thoracic Oncology
[2] Osaka Medical Center for Cancer and Cardiovascular Disease,Nursing Department
来源：
International Journal of Clinical Oncology | 2017年 / 22卷
关键词：
Aprepitant; Breakthrough emesis; Moderately emetogenic chemotherapy; Lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：600 / 604
页数：4
相关论文
共 50 条
  • [1] Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Inoue, Takako
    Kimura, Madoka
    Uchida, Junji
    Nishino, Kazumi
    Kumagai, Toru
    Taniguchi, Junko
    Imamura, Fumio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (03) : 600 - 604
  • [2] Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy
    Molassiotis, Alex
    Nguyen, Allison Martin
    Rittenberg, Cynthia N.
    Makalinao, Alex
    Carides, Alexandra
    FUTURE ONCOLOGY, 2013, 9 (10) : 1443 - 1450
  • [3] A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
    Zelek, Laurent
    Debourdeau, Philippe
    Bourgeois, Hugues
    Wagner, Jean Philippe
    Brocard, Fabien
    Lefeuvre-Plesse, Claudia
    Chauffert, Bruno
    Leheurteur, Marianne
    Bachet, Jean-Baptiste
    Simon, Helene
    Mayeur, Didier
    Scotte, Florian
    ONCOLOGIST, 2021, 26 (10): : E1870 - E1879
  • [4] The efficacy of aprepitant in salvage treatment of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy for patients with gastrointestinal cancer
    Qiaoyan Gong
    Jiangfang Tian
    Yulian Jiang
    Xiaofen Li
    Lingyan Zhou
    Dan Cao
    International Journal of Clinical Oncology, 2021, 26 : 1091 - 1098
  • [5] The efficacy of aprepitant in salvage treatment of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy for patients with gastrointestinal cancer
    Gong, Qiaoyan
    Tian, Jiangfang
    Jiang, Yulian
    Li, Xiaofen
    Zhou, Lingyan
    Cao, Dan
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (06) : 1091 - 1098
  • [6] A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
    Winnie Yeo
    F. K. F. Mo
    J. J. S. Suen
    W. M. Ho
    S. L. Chan
    W. Lau
    J. Koh
    W. K. Yeung
    W. H. Kwan
    K. K. C. Lee
    T. S. K. Mok
    A. N. Y. Poon
    K. C. Lam
    E. K. Hui
    B. Zee
    Breast Cancer Research and Treatment, 2009, 113 : 529 - 535
  • [7] A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
    Yeo, Winnie
    Mo, F. K. F.
    Suen, J. J. S.
    Ho, W. M.
    Chan, S. L.
    Lau, W.
    Koh, J.
    Yeung, W. K.
    Kwan, W. H.
    Lee, K. K. C.
    Mok, T. S. K.
    Poon, A. N. Y.
    Lam, K. C.
    Hui, E. K.
    Zee, B.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (03) : 529 - 535
  • [8] Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Zelek, Laurent
    Navari, Rudolph
    Aapro, Matti
    Scotte, Florian
    CANCER MEDICINE, 2023, 12 (15): : 15769 - 15776
  • [9] Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
    Warr, DG
    Hesketh, PJ
    Gralla, RJ
    Muss, HB
    Herrstedt, J
    Eisenberg, PD
    Raftopoulos, H
    Grunberg, SM
    Gabriel, M
    Rodgers, A
    Bohidar, N
    Klinger, G
    Hustad, CM
    Horgan, KJ
    Skobieranda, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2822 - 2830
  • [10] The Use of Olanzapine Versus Metoclopramide for the Treatment of Breakthrough Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
    Navari, Rudolph
    Nagy, Cindy
    Gray, Sarah
    PSYCHO-ONCOLOGY, 2013, 22 : 31 - 31
12345